Literature DB >> 15556647

Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways.

Juerg Gertsch1, Roland Schoop, Urs Kuenzle, Andy Suter.   

Abstract

Echinacea plant preparations are widely used in the prevention and treatment of common cold. However, so far no molecular mechanism of action has been proposed. We analyzed the standardized tincture Echinaforce and found that it induced de novo synthesis of tumor necrosis factor alpha (TNF-alpha) mRNA in primary human monocytes/macrophages, but not TNF-alpha protein. Moreover, LPS-stimulated TNF-alpha protein was potently inhibited in the early phase but prolonged in the late phase. A study of the main constituents of the extract showed that the alkylamides dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (1/2), trienoic (3) and dienoic acid (4) derivatives are responsible for this effect. The upregulation of TNF-alpha mRNA was found to be mediated by CB2 receptors, increased cAMP, p38/MAPK and JNK signaling, as well as NF-kappaB and ATF-2/CREB-1 activation. This study is the first to report a possible molecular mechanism of action of Echinacea, highlighting the role of alkylamides as potent immunomodulators and potential ligands for CB2 receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15556647     DOI: 10.1016/j.febslet.2004.10.064

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  44 in total

1.  Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.

Authors:  Joseph E Henriquez; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2019-02-23       Impact factor: 4.219

2.  Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action?

Authors:  Jürg Gertsch
Journal:  Commun Integr Biol       Date:  2008

Review 3.  Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Authors:  Jerome Sarris; Erica McIntyre; David A Camfield
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 4.  Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2.

Authors:  Lindsay K Caesar; Nadja B Cech
Journal:  Nat Prod Rep       Date:  2019-06-19       Impact factor: 13.423

5.  Enrichment of Echinacea angustifolia with Bauer alkylamide 11 and Bauer ketone 23 increased anti-inflammatory potential through interference with cox-2 enzyme activity.

Authors:  Carlie A Lalone; Nan Huang; Ludmila Rizshsky; Man-Yu Yum; Navrozedeep Singh; Cathy Hauck; Basil J Nikolau; Eve S Wurtele; Marian L Kohut; Patricia A Murphy; Diane F Birt
Journal:  J Agric Food Chem       Date:  2010-08-11       Impact factor: 5.279

Review 6.  Echinacea for preventing and treating the common cold.

Authors:  Marlies Karsch-Völk; Bruce Barrett; David Kiefer; Rudolf Bauer; Karin Ardjomand-Woelkart; Klaus Linde
Journal:  Cochrane Database Syst Rev       Date:  2014-02-20

Review 7.  Biosynthesis and function of polyacetylenes and allied natural products.

Authors:  Robert E Minto; Brenda J Blacklock
Journal:  Prog Lipid Res       Date:  2008-03-13       Impact factor: 16.195

Review 8.  CB2 receptors in reproduction.

Authors:  M Maccarrone
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

9.  Integrating metabolomics and transcriptomics data to discover a biocatalyst that can generate the amine precursors for alkamide biosynthesis.

Authors:  Ludmila Rizhsky; Huanan Jin; Michael R Shepard; Harry W Scott; Alicen M Teitgen; M Ann Perera; Vandana Mhaske; Adarsh Jose; Xiaobin Zheng; Matt Crispin; Eve S Wurtele; Dallas Jones; Manhoi Hur; Elsa Góngora-Castillo; C Robin Buell; Robert E Minto; Basil J Nikolau
Journal:  Plant J       Date:  2016-09-27       Impact factor: 6.417

10.  Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Larissa Jakiw; Andrei I Khlebnikov; Christie L Blaskovich; Mark A Jutila; Mark T Quinn
Journal:  J Immunol       Date:  2009-10-21       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.